Hypertension. 2003;41:64-68
Published online before print November 18, 2002, doi: 10.1161/01.HYP.0000044937.95080.E9
Published online before print November 18, 2002, doi: 10.1161/01.HYP.0000044937.95080.E9
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:64.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
From the Department of Internal Medicine, Mito Red Cross Hospital (A.S.), Ibaraki; the Department of Internal Medicine, Keio University (K.H., T.S.), Tokyo; and the Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women’s Medical University (M.N.), Tokyo, Japan.
Correspondence to Atsuhisa Sato, MD, PhD, Department of Internal Medicine, Mito Red Cross Hospital, 3-12-48 San-nomaru, Mito city, Ibaraki, 310-0011, Japan. E-mail atsu-sa{at}pb3.so-net.ne.jp
It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape). We have examined the role of aldosterone escape in 45 patients with type 2 diabetes and early nephropathy treated with an ACE inhibitor for 40 weeks. With treatment, there was a 40% reduction in average urinary albumin excretion, although urinary albumin excretion in patients with aldosterone escape (18 patients) was significantly higher than that in patients without escape (27 patients). In the 18 patients with escape, spironolactone (25 mg/d) was added to ACE inhibitor treatment in 13. After a 24-week study period, urinary albumin excretion and left ventricular mass index were significantly reduced without blood pressure change. In conclusion, the present study demonstrates that aldosterone escape is observed in 40% of patients with type 2 diabetes with early nephropathy despite the use of ACE inhibitors. Our study suggests the possibility that aldosterone blockade may represent optimal therapy for patients with early diabetic nephropathy who show aldosterone escape during ACE inhibitor treatment and who no longer show maximal antiproteinuric effects of ACE inhibition. Additional, larger, prospectively randomized, double-blind studies will be needed before adaptation of this strategy.
Key Words: aldosterone • angiotensin-converting enzyme • diabetic nephropathy hemodialysis • hypertrophy • ventricular function, left
This article has been cited by other articles:
 |
|
 |
|
  Y. S. Kang, G. J. Ko, M. H. Lee, H. K. Song, S. Y. Han, K. H. Han, H. K. Kim, J. Y. Han, and D. R. Cha Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats Nephrol. Dial. Transplant., August 5, 2008; (2008) gfn448v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Oyamada, M. Sone, K. Miyashita, K. Park, D. Taura, M. Inuzuka, T. Sonoyama, H. Tsujimoto, Y. Fukunaga, N. Tamura, et al. The Role of Mineralocorticoid Receptor Expression in Brain Remodeling after Cerebral Ischemia Endocrinology, August 1, 2008; 149(8): 3764 - 3777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Graf, T. Hucko, and P. Stawowy Cardiac Benefits of Mineralocorticoid Receptor Inhibition in Renal Failure Hypertension, August 1, 2008; 52(2): 209 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Siragy and C. Xue Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats Exp Physiol, July 1, 2008; 93(7): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Otani, F. Otsuka, K. Inagaki, J. Suzuki, T. Miyoshi, Y. Kano, J. Goto, T. Ogura, and H. Makino Aldosterone Breakthrough Caused by Chronic Blockage of Angiotensin II Type 1 Receptors in Human Adrenocortical Cells: Possible Involvement of Bone Morphogenetic Protein-6 Actions Endocrinology, June 1, 2008; 149(6): 2816 - 2825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Vogt, F. Waanders, F. Boomsma, D. de Zeeuw, and G. Navis Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan J. Am. Soc. Nephrol., May 1, 2008; 19(5): 999 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gauer, V. Segitz, and M. Goppelt-Struebe Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3154 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Joffe, R. Y. Kwong, M. D. Gerhard-Herman, C. Rice, K. Feldman, and G. K. Adler Beneficial Effects of Eplerenone Versus Hydrochlorothiazide on Coronary Circulatory Function in Patients with Diabetes Mellitus J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2552 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Catena, G. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna, and L. A. Sechi Relationships of Plasma Renin Levels with Renal Function in Patients with Primary Aldosteronism Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Bobadilla and G. Gamba New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone Am J Physiol Renal Physiol, July 1, 2007; 293(1): F2 - F9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hayashi, S. Wakino, N. Sugano, Y. Ozawa, K. Homma, and T. Saruta Ca2+ Channel Subtypes and Pharmacology in the Kidney Circ. Res., February 16, 2007; 100(3): 342 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Rump Secondary rise of albuminuria under AT1-receptor blockade--what is the potential role of aldosterone escape? Nephrol. Dial. Transplant., January 1, 2007; 22(1): 5 - 8. [Full Text] [PDF]
|
|
|
|
|
|
J. Perez-Rojas, J. A. Blanco, C. Cruz, J. Trujillo, V. S. Vaidya, N. Uribe, J. V. Bonventre, G. Gamba, and N. A. Bobadilla Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity Am J Physiol Renal Physiol, January 1, 2007; 292(1): F131 - F139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nagase, S. Yoshida, S. Shibata, T. Nagase, T. Gotoda, K. Ando, and T. Fujita Enhanced Aldosterone Signaling in the Early Nephropathy of Rats with Metabolic Syndrome: Possible Contribution of Fat-Derived Factors J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3438 - 3446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lepenies and M. Quinkler MR blockade in patients with chronic renal disease--not the more the merrier, but the earlier the better Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3343 - 3344. [Full Text] [PDF]
|
|
|
|
 |
|
 N.C. Edwards, R.P. Steeds, C.J. Ferro, and J.N. Townend The treatment of coronary artery disease in patients with chronic kidney disease QJM, November 1, 2006; 99(11): 723 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guo, D. Martinez-Vasquez, G. P. Mendez, M. F. Toniolo, T. M. Yao, E. M. Oestreicher, T. Kikuchi, N. Lapointe, L. Pojoga, G. H. Williams, et al. Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus Endocrinology, November 1, 2006; 147(11): 5363 - 5373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Epstein, G. H. Williams, M. Weinberger, A. Lewin, S. Krause, R. Mukherjee, R. Patni, and B. Beckerman Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 940 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-P. Sun, M. Kohno, P. Guo, Y. Nagai, K. Miyata, Y.-Y. Fan, S. Kimura, H. Kiyomoto, K. Ohmori, D.-T. Li, et al. Involvements of Rho-Kinase and TGF-beta Pathways in Aldosterone-Induced Renal Injury J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2193 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.P. Habashi, D.P. Judge, T.M. Holm, R.D Cohn, B. Loeys, T.K. Cooper, L. Myers, E.C. Klein, G. Liu, C. Calvi, et al. Losartan in Marfan Syndrome--Beyond Blood Pressure Lowering: Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Science 312: 117-121, 2006 J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1759 - 1764. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Ponda and T. H. Hostetter Aldosterone Antagonism in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 668 - 677. [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Sechi, M. Novello, R. Lapenna, S. Baroselli, E. Nadalini, G. L. Colussi, and C. Catena Long-term renal outcomes in patients with primary aldosteronism. JAMA, June 14, 2006; 295(22): 2638 - 2645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Han, C.-H. Kim, H.-S. Kim, Y.-H. Jee, H.-K. Song, M.-H. Lee, K.-H. Han, H.-K. Kim, Y.-S. Kang, J.-Y. Han, et al. Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1362 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Covic, P. Gusbeth-Tatomir, and D. J. A. Goldsmith Is it time for spironolactone therapy in dialysis patients? Nephrol. Dial. Transplant., April 1, 2006; 21(4): 854 - 858. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chrysostomou, E. Pedagogos, L. MacGregor, and G. J. Becker Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 256 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miyata, M. Rahman, T. Shokoji, Y. Nagai, G.-X. Zhang, G.-P. Sun, S. Kimura, T. Yukimura, H. Kiyomoto, M. Kohno, et al. Aldosterone Stimulates Reactive Oxygen Species Production through Activation of NADPH Oxidase in Rat Mesangial Cells J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2906 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nagai, K. Miyata, G.-P. Sun, M. Rahman, S. Kimura, A. Miyatake, H. Kiyomoto, M. Kohno, Y. Abe, M. Yoshizumi, et al. Aldosterone Stimulates Collagen Gene Expression and Synthesis Via Activation of ERK1/2 in Rat Renal Fibroblasts Hypertension, October 1, 2005; 46(4): 1039 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Quinkler, D. Zehnder, K. S. Eardley, J. Lepenies, A. J. Howie, S. V. Hughes, P. Cockwell, M. Hewison, and P. M. Stewart Increased Expression of Mineralocorticoid Effector Mechanisms in Kidney Biopsies of Patients With Heavy Proteinuria Circulation, September 6, 2005; 112(10): 1435 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kumar and P. H Winocour Review: Dual blockade of the renin angiotensin system in diabetes -- rationale and risks The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 266 - 271. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Rossing, K. J. Schjoedt, U. M. Smidt, F. Boomsma, and H.-H. Parving Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study Diabetes Care, September 1, 2005; 28(9): 2106 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Xue and H. M. Siragy Local Renal Aldosterone System and Its Regulation by Salt, Diabetes, and Angiotensin II Type 1 Receptor Hypertension, September 1, 2005; 46(3): 584 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yoneda, H. Sanada, J. Yatabe, S. Midorikawa, S. Hashimoto, M. Sasaki, T. Katoh, T. Watanabe, P. M. Andrews, P. A. Jose, et al. Differential Effects of Angiotensin II Type-1 Receptor Antisense Oligonucleotides on Renal Function in Spontaneously Hypertensive Rats Hypertension, July 1, 2005; 46(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fiebeler, J. Nussberger, E. Shagdarsuren, S. Rong, G. Hilfenhaus, N. Al-Saadi, R. Dechend, M. Wellner, S. Meiners, C. Maser-Gluth, et al. Aldosterone Synthase Inhibitor Ameliorates Angiotensin II-Induced Organ Damage Circulation, June 14, 2005; 111(23): 3087 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]
|
|
|
|
|
|
A. Nishiyama, L. Yao, Y. Fan, M. Kyaw, N. Kataoka, K. Hashimoto, Y. Nagai, E. Nakamura, M. Yoshizumi, T. Shokoji, et al. Involvement of Aldosterone and Mineralocorticoid Receptors in Rat Mesangial Cell Proliferation and Deformability Hypertension, April 1, 2005; 45(4): 710 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz Diabetic Nephropathy: Diagnosis, Prevention, and Treatment Diabetes Care, January 1, 2005; 28(1): 164 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Marshall Recent advances in diabetic nephropathy Postgrad. Med. J., November 1, 2004; 80(949): 624 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gross and F. Pistrosch Hyperkalaemia: again Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2163 - 2166. [Full Text] [PDF]
|
|
|
|
|
|
G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, and L. Deferrari Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S6 - 11. [Abstract] [Full Text]
|
|
|
|
|
|
W. A. Wilmer, B. H. Rovin, C. J. Hebert, S. V. Rao, K. Kumor, and L. A. Hebert Management of Glomerular Proteinuria: A Commentary J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3217 - 3232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yonemura, H. Yasuda, and A. Hishida Distinct Responses of Membranoproliferative Glomerulonephritis-Related Proteinuria to Spironolactone with and without Angiotensin II Blockade Ann Intern Med, November 4, 2003; 139(9): W-79 - W-79. [Full Text] [PDF]
|
|
|
|
|
|
M. Epstein Aldosterone receptor blockade and the role of eplerenone: evolving perspectives Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1984 - 1992. [Full Text] [PDF]
|
|
|
|
|
|
T. H. Hostetter and H. N. Ibrahim Aldosterone in Chronic Kidney and Cardiac Disease J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2395 - 2401. [Abstract] [Full Text] [PDF]
|
|